

Drug	Schedule
Oxymorphone (9652) .....	II
Racemethorphan (9732) .....	II
Racemorphan (9733) .....	II

The company plans to manufacture small quantities of the listed controlled substances in bulk for distribution to its customers for use as reference standards.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a), and determined that the registration of Chemtos, LLC, to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Chemtos, LLC, to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history.

Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed.

Dated: December 14, 2012.

**Joseph T. Rannazzisi,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 2012-30781 Filed 12-20-12; 8:45 am]

**BILLING CODE 4410-09-P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**Manufacturer of Controlled Substances, Notice of Registration, Halo Pharmaceutical, Inc.**

By Notice dated July 30, 2012, and published in the **Federal Register** on August 7, 2012, 77 FR 47114, Halo Pharmaceutical, Inc., 30 North Jefferson Road, Whippany, New Jersey 07981, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances:

Drug	Schedule
Dihydromorphone (9145) .....	I
Hydromorphone (9150) .....	II

Dihydromorphone is an intermediate in the manufacture of Hydromorphone and is not for commercial distribution.

The company plans to manufacture Hydromorphone HCL for sale to other manufacturers, and for the manufacture of other controlled substance dosage units for distribution to its customers.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a), and determined that the registration of Halo Pharmaceutical, Inc., to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Halo Pharmaceutical, Inc., to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history.

Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed.

Dated: December 14, 2012.

**Joseph T. Rannazzisi,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 2012-30774 Filed 12-20-12; 8:45 am]

**BILLING CODE 4410-09-P**

**NATIONAL FOUNDATION ON THE ARTS AND THE HUMANITIES**

**Arts Advisory Panel Meeting**

**AGENCY:** National Endowment for the Arts, National Foundation on the Arts and Humanities.

**ACTION:** Notice of Meeting.

**SUMMARY:** Pursuant to Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), as amended, notice is hereby given that seven meetings of the Arts Advisory Panel to the National Council on the Arts will be held at the Nancy Hanks Center, 1100 Pennsylvania Avenue NW., Washington, DC 20506 (unless otherwise noted) as follows (ending times are approximate):

*International* (application review): By teleconference. This meeting will be closed.

*Dates:* January 8, 2013; 1:00 p.m. to 2:00 p.m. e.s.t.

*Folk & Traditional Arts* (application review): In room 716. This meeting will be closed.

*Dates:* January 11, 2013; 9:00 a.m. to 5:30 p.m. e.s.t.

*State & Regional* (review of state partnership agreements): In Room 716. This meeting will be open.

*Dates:* January 16-17, 2013; From 9:00 a.m. to 5:00 p.m. e.s.t. on January 16th and from 9:00 a.m. to 3:30 p.m. e.s.t. on January 17th.

*Music* (review of nominations): 3 Columbus Circle, 12th Floor, New York, NY 10019 and by teleconference. This meeting will be closed.

*Dates:* January 15, 2013, from 9:00 a.m. to 10:15 a.m. e.s.t.

*State & Regional* (review of regional partnership agreements): By teleconference. This meeting will be open.

*Dates:* January 30, 2013; From 3:00 p.m. to 4:00 p.m. e.s.t.

*Folk & Traditional Arts* (review of nominations): In room 716. This meeting will be closed.

*Dates:* January 29-February 1, 2013; from 9:00 a.m. to 5:30 p.m. e.s.t. on January 29th-31st and from 9:00 a.m. to 1:00 p.m. e.s.t. on February 1st.

*Research* (application review): In Room 627. This meeting will be closed.

*Dates:* January 29-30, 2013; From 9:00 a.m. to 5:30 p.m. e.s.t. on January 29th and from 9:00 a.m. to 5:00 p.m. e.s.t. on January 30th.

**FOR FURTHER INFORMATION CONTACT:**

Further information with reference to these meetings can be obtained from Ms. Kathy Plowitz-Worden, Office of Guidelines & Panel Operations, National Endowment for the Arts, Washington, DC 20506; [plowitzk@arts.gov](mailto:plowitzk@arts.gov) or call 202/682-5691.

**SUPPLEMENTARY INFORMATION:** The closed portions of meetings are for the purpose of Panel review, discussion, evaluation, and recommendations on financial assistance under the National Foundation on the Arts and the Humanities Act of 1965, as amended, including information given in confidence to the agency. In accordance with the determination of the Chairman of February 15, 2012, these sessions will be closed to the public pursuant to subsection (c)(6) of section 552b of Title 5, United States Code.

Dated: December 18, 2012.

**Kathy Plowitz-Worden,**

*Panel Coordinator, National Endowment for the Arts.*

[FR Doc. 2012-30759 Filed 12-20-12; 8:45 am]

**BILLING CODE 7537-01-P**